NVS - Novartis • Financials

Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year	Revenue	EBITDA	Net Inc	Net Mrg	EPS	Equity	ROE	Net Debt Aj	ND/EBITDA Aj	OCF Aj	Capex	FCF	Free Aj	Buyback	Dividend	Payout	DY
12/2016	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2017	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2018	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2019	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2020	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2021	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2022	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2023	46,660	18,152	-	32%	7.1	46,667	32%	10,183	0.56	13,593	-2,753	-14,278	10,840	-8,719	-7,255	49%	3.5%
12/2024	51,722	20,658	-	23%	5.9	44,046	27%	16,141	0.78	16,575	-3,814	-11,742	12,761	-8,331	-7,624	64%	3.9%
12/2025	56,674	22,919	-	25%	7.2	46,130	30%	21,947	0.96	18,048	-3,900	-14,867	14,148	-9,212	-7,818	56%	2.9%

To see all financials—including updated, you must be Premium.